MP

Munni Pandey

Active Director Director DIN 08356035
DIN 08356035 First appointment Feb 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2019
Shareholding value •••• Premium profile

About Munni Pandey

Data last updated:

Munni Pandey is a Director at Nexilon Pharmaceutical Private Limited (since 2019). The company operates in Pharma. Nexilon Pharmaceutical Private Limited reported revenue of ₹10.5 Lakh (FY 2023).

DIN 08356035
Primary Designation Director
Industry Pharma
First Appointment 08 Feb 2019
Oldest Company Age 7 yrs
Largest company Nexilon Pharmaceutical Private Limited · ₹10.5 Lakh (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director08 Feb 20192019₹10.5 Lakh (FY 2023)Active

Directorship timeline

Open interactive timeline →
Nexilon Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Munni Pandey

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Munni Pandey

Munni Pandey currently holds 1 directorship: Nexilon Pharmaceutical Private Limited (Director, since 08 Feb 2019, revenue ₹10.5 Lakh (FY 2023)).

Munni Pandey was first appointed on 08 Feb 2019 as Director at Nexilon Pharmaceutical Private Limited.

The current boards of Munni Pandey's companies include Ranjeet Kumar (Nexilon Pharmaceutical Private Limited), Santosh Kumar Pandey (Nexilon Pharmaceutical Private Limited), Tilak Bihari (Nexilon Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available